ACTUALIDAD

A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)

 

RESEARCHER:

Prof. Luis Fernández-Vega Sanz

 RECLUTANDO 

 

A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)


INDICATION: Pacientes con degeneración macular asociada a la edad (DMAE húmeda).
TREATMENT: OPT-302
PROMOTOR: OPTHEA
Déjanos tus datos
Nos pondremos en contacto contigo
Please enable JavaScript in your browser to complete this form.
Casillas de verificación
REQUEST APPOINTMENT
We will contact you
Please enable JavaScript in your browser to complete this form.
Casillas de verificación